Central serous chorioretinopathy by Liegl, Raffael & Ulbig, Michael W.
E-Mail karger@karger.com
 Review 
 Ophthalmologica 2014;232:65–76 
 DOI: 10.1159/000360014 
 Central Serous Chorioretinopathy 
 Raffael Liegl    Michael W. Ulbig 
 Department of Ophthalmology, Ludwig Maximilian University of Munich,  Munich , Germany 
rous retinal detachment typically affecting the posterior 
pole, particularly the macular region (fig. 1). The exact 
underlying mechanism of that disease was not known in 
those days, nor is it fully understood today. Von Graefe 
introduced the idea of retinitis, implying that there was 
an inflammatory component of this disease, based on his 
observation that all patients with this condition during 
that time also suffered from syphilis  [2] . Nowadays it has 
been common to refer to this condition as ‘central serous 
chorioretinopathy’ (CSC), a term mainly coined by Don-
ald Gass in the late 1960s; however, other synonyms such 
as ‘(chorio)retinopathia centralis serosa’ or ‘central se-
rous retinopathy’ are also still in use.
 The evolution of the term ‘central serous chorioreti-
nopathy’ has always been closely linked to the concep-
tion of the pathomechanism underlying this disease at 
the respective point in time. Horniker  [3] was the first 
to revise von Graefe’s idea of an inflammation as the 
underlying reason for the disease, as he observed pa-
tients with this condition without any previous history 
of syphilis. Rather, he believed that it was a constitu-
tional angioneurosis which caused vasospasm and sub-
sequent exudation in these patients  [3] . Later concepts 
included Gifford and Marquardt’s  [4] ‘central angio-
spastic retinopathy’ in 1939 as they believed an angi-
opathy with an abnormal vessel muscle tone was the 
reason for this disorder.
 The concept of a vasospastic disease did not change 
until fluorescein angiography (FA) was introduced in 
ophthalmology, allowing a better understanding of the 
disease. In 1965 Maumenee  [5] was the first to publish his 
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 Abstract 
 The pathogenesis of central serous chorioretinopathy (CSC) 
is still not fully understood. The involvement of corticoste-
roids is undisputed, although their exact role has not been 
clarified; other parts of the underlying mechanism of CSC 
have been mainly elucidated by imaging techniques such as 
fluorescein and indocyanine green angiography. Even 
though most cases of CSC are self-limiting, severe as well as 
recurrent courses exist, and for these patients only a limited 
number of treatment options are available: laser photoco-
agulation, with a risk of scotoma and choroidal neovascular-
ization, and photodynamic therapy. In this review article, we 
give an overview of its epidemiology, the current under-
standing of its pathogenesis as well as systemic and ocular 
risk factors. We illuminate modern diagnostic tools as well as 
current treatment options in the context of CSC, particularly 
in the light of a better understanding of corticosteroids and 
their receptors involved in its pathogenesis. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 In 1866 Albrecht von Graefe  [1] described a disease 
that he referred to as ‘recurrent central retinitis’. Patients 
suffering from this condition showed a circumscribed se-
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observation on leakage, which he made during FA at the 
level of the retinal pigment epithelium (RPE), suggesting 
involvement of both the RPE and the choroid. More de-
tailed observations and a further understanding of the 
condition, mainly through better-characterized FA find-
ings, finally led to the term ‘idiopathic central serous cho-
roidopathy’ by Gass, which over time has been adjusted 
to ‘central serous chorioretinopathy’ owing to the knowl-
edge about the hyperpermeability of the RPE  [6, 7] .
 In this review article, we give an overview of the epide-
miology of CSC, the current understanding of its patho-
genesis as well as systemic and ocular risk factors. We il-
luminate modern diagnostic tools in the context of CSC 
as well as current treatment options, particularly in the 
light of a better understanding of corticosteroids and 
their receptors involved in the pathogenesis.
 Epidemiology 
 Although CSC has not been in the focus of research 
over the last years, clinicians are often confronted with 
this disease as it is supposed to be the fourth most com-
mon nonsurgical retinopathy after age-related macular 
degeneration, diabetic retinopathy and branch retinal 
vein occlusion  [8] . Historically, its occurrence has mainly 
been associated with men in their 30s to 40s. Indeed, al-
though only one population-based study and no system-
ic epidemiologic survey of CSC has been carried out, a 
large number of single studies support the idea of men 
being more often affected than women, presenting male-
to-female ratios of up to 8: 1  [9–14] . The mean age of pa-
tients affected is quoted variably in these studies but 
seems to be slightly higher than usually assumed, with a 
peak at around 40–45 years in men, although some stud-
ies suggest even higher mean ages for men  [15–18] and 
particularly for women and patients with chronic CSC  [8, 
11, 19] . In addition, cases of CSC in children have been 
reported  [20, 21] .
 In terms of occurrence among different races, there 
seems to be a shift in distribution toward people of His-
panic, Asian and Caucasian descent  [22, 23] . People of 
African descent seem to be affected notably less frequent-
ly according to some authors, although it has been dis-
cussed that this conception might be wrong and derived 
from the reduced availability of medical infrastructure in 
poor countries for adequately diagnosing this condition 
 [24] . Some authors also report on more aggressive cours-
es of the disease in Black people  [25, 26] .
 Pathogenesis 
 CSC has long been considered to be a vasospastic dis-
ease. This conception has been largely abandoned with 
the advent of diagnostic imaging techniques such as FA 
and indocyanine green angiography (ICGA). However, 
its pathogenesis still remains unclear in spite of these ad-
vances. Numerous hypotheses have been proclaimed and 
mainly involve the RPE as well as the choroid as being 
central contributors to subretinal fluid accumulation 
with subsequent detachment of the neurosensory retina 
 [27] .
 The current idea of the pathophysiology of CSC main-
ly proclaims choroidal vascular hyperpermeability to be 
the major reason for the increased tissue hydrostatic pres-
sure beneath the RPE that can eventually lead to disinteg-
rity of the continuity of the RPE  [28] . The observation 
that the retinal detachment regresses once the fluorescein 
leakage from one or multiple sites stops, as found by FA, 
has been interpreted as showing that there was a lesion of 
the RPE leading to subretinal accumulation of fluid orig-
inating from the choroid  [16, 29] . ICGA findings show a 
staining of the inner choroid in the midphase of the an-
giogram, suggesting choroidal vascular hyperpermeabil-
ity which may arise from venous congestion and ischemia 
 [30–35] . Under physiologic conditions, the balance be-
tween oncotic and hydrostatic pressure usually leads to 
fluid flowing from the retina toward the choroid  [16] . In 
 Fig. 1. Color fundus photography of the left eye of a 35-year-old 
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CSC, however, an extensive hydrostatic pressure within 
the choroid leads to fluid being squeezed out of the cho-
roidal vascular system and subsequently accumulating 
underneath the RPE  [36, 37] . Once the tissue hydrostatic 
pressure beneath the RPE is high enough, it is believed 
that it pushes the RPE forward, which in turn results in 
discontinuity of the RPE barrier, leading to pigment epi-
thelial detachment (PED) and pinpoint areas of leakage 
often referred to as ‘microrips’ or ‘blowouts’  [38, 39] . In 
addition, the damage to the RPE is presumed to lead to an 
aggravation of this condition, since the RPE may be re-
stricted in its ability to pump fluid out of the subretinal 
space. This theory is further supported by the clinical 
finding of leaks in the RPE demonstrated by FA at the 
level of choroidal vascular hyperpermeability  [40, 41] . 
However, choroidal thickening as seen by OCT and inner 
choroidal staining as signs of increased choroidal hyper-
permeability can also be observed in other regions of the 
retina not directly adjacent to a PED or microrip. Al-
though this might counteract the idea of a PED caused by 
fluid pushing from the choroid toward the RPE, one ex-
planation includes the typical area of clinically observed 
PED in the foveal region with presumably weaker attach-
ment of the thinner retina and therefore greater predis-
position to serous retinal detachment  [8] .
 The role of the RPE is still only vaguely understood 
and other ideas of the pathophysiology of CSC also in-
clude an abnormal polarity of some of the RPE cells lead-
ing to fluid being pumped from the choroid to the retina 
 [42] . This concept, however, has some weaknesses as it 
fails to explain the occurrence of PED and why some de-
polarized RPE cells overwhelm the surrounding, normal-
ly aligned RPE cells in terms of fluid flow direction.
 The mechanistic hypothesis proposing that fluid com-
ing from hyperpermeable choroidal vessels leads to in-
creased tissue hydrostatic pressure – which results in RPE 
damage – seems reasonable; however, it does not explain 
why the choroidal vascular system would develop an in-
creased permeability.
 Systemic and Ocular Risk Factors 
 Several risk factors for the development of CSC exist, 
but they are not fully understood, and only high serum 
glucocorticoid levels seem to be unambiguously related 
to the occurrence of CSC  [18, 43] . Increased glucocorti-
costeroid and serum catecholamine levels have been 
found in patients with CSC  [12, 44–47] . However, no in-
creased risk for the development of CSC has been ob-
served after intake of sympathomimetic agents alone 
 [27] . Furthermore, no improvement in the course of CSC 
was seen after intake of β-blockers, suggesting that the 
simultaneous upregulation of serum catecholamine levels 
in a situation of increased glucocorticosteroid levels is 
due to a stress response, rather than suggesting that the 
disease triggers this increased expression  [48, 49] . With 
respect to corticosteroids, however, several studies proved 
an association of increased levels with CSC for corticoste-
roids of endogenous and particularly exogenous origin 
 [50, 51] . Glucocorticoid as well as mineralocorticoid hor-
mones belong to the same group referred to as corticoste-
roids synthesized from cholesterol. It is well known that 
corticosteroids have an impact on the RPE, Bruch’s mem-
brane and the choriocapillaris, possibly altering their per-
meability directly or secondarily due to vascular autoreg-
ulation or vascular reactivity  [52–54] . It remains unclear, 
though, why elevated serum corticosteroid levels may 
trigger CSC, while intraocular injections of triamcino-
lone or similar drugs are very rarely associated with the 
development of CSC  [16, 55, 56] .
 One of the first risk factors identified was having a type 
A personality  [23] . People referred to as having a type A 
personality are usually characterized by a highly status-
conscious, ambitious and rigidly organized pattern of be-
havior  [57] . Further risk factors that have been proposed 
include pregnancy, alcohol consumption, untreated hy-
pertension, use of antibiotics, bone marrow or organ 
transplantation, infection of the respiratory tract and in-
fection with  Helicobacter pylori  [12, 44, 58–63] .
 Clinical Presentation 
 CSC typically occurs unilaterally in younger patients 
and is characterized by decreased and distorted vision, 
often associated with metamorphopsia, micropsia, mild 
dyschromatopsia and reduced contrast sensitivity  [64] . 
However, bilateral affection occurs and is more often seen 
in elderly patients.
 CSC can occur in an acute or chronic form, but no 
generally accepted duration has been defined for the 
chronic form; many authors tend to speak of chronic CSC 
if symptoms last longer than 3 months, but other authors 
speak of chronicity if CSC alterations and symptoms are 
present for more than 6 months  [65–67] . Visual acuity is 
usually reduced to 20/30 to 20/60 and can in some cases 
be corrected with a weak plus lens due to a slightly elevat-
ed retina level causing mild hypermetropia  [16, 64] . 
While acute CSC usually resolves spontaneously with re-
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turn to normal or almost normal visual acuity, recurrent 
forms are not rare and may be seen in more than 50% of 
patients suffering from CSC  [68, 69] . Clinically, it most 
commonly presents as a localized, circumscribed area of 
retinal detachment most often in the macular region. The 
subretinal fluid is usually clear in acute cases but may also 
have a hazy or fibrinous appearance, while additional 
blood is very uncommon in CSC. The RPE may show ar-
eas of disturbance or abnormal pigmentation variable in 
size within the detachment of the sensory retina, some-
times even leading to PED.
 Chronic CSC, on the other hand, typically goes along 
with more advanced stages of RPE alteration, which my 
lead to a distinct and permanent loss of visual acuity. This 
form has also been termed ‘diffuse retinal pigment epi-
theliopathy’ and implies an advanced age at the time of 
the diagnosis  [17] . Detachments of the neurosensory ret-
ina in  these patients differ from those in patients with 
acute CSC as they appear less elevated and may show 
thinning of the retina as well as atrophy of the underlying 
RPE. The prolonged detachment may be caused by pho-
toreceptor and RPE damage and results in unfavorable 
visual acuity; moreover, a minority of cases might even 
develop choroidal neovascularization (CNV) and RPE 
tears with subsequent risk of severe visual impairment 
 [70, 71] .
 Another form of CSC is characterized by large, usually 
multiple, sectors of bullous, serous retinal and/or RPE de-
tachments. It is a rare form and may occur secondary to 
CSC. Typical features include greater numbers and sizes 
of areas of choroidal hyperpermeability and bullous reti-
nal detachment which often extends by gravitation to the 
inferior part of the retina. It seems to be more frequent in 
Japanese people and has been reported after organ trans-
plantation as well  [72–74] .
 Imaging in CSC 
 Imaging techniques such as FA or ICGA have been 
very helpful tools for gaining a better understanding of 
the pathophysiology of CSC and for supporting a diagno-
sis of CSC. However, a better knowledge of risk factors 
and patient characteristics as well as gradual improve-
ments in clinical description have led to the situation that 
most CSC cases can be sufficiently diagnosed without fur-
ther need for imaging devices. Apart from invasive imag-
ing tools such as FA and ICGA, novel developments in-
cluding OCT with enhanced depth imaging and fundus 
autofluorescence imaging (FAF) may contribute to a 
deeper understanding of the disease.
 Fluorescein Angiography 
 Angiographic findings for acute CSC are character-
ized by focal fluorescein leaks at the level of the RPE 
leading to subretinal accumulation of dye  [75] . Three 
different manifestations have been described and in-
clude ‘smokestack leak’ and ‘inkblot leak’  patterns (fig. 2), 
a b
 Fig. 2. Widefield angiography of the right eye of a 42-year-old male patient with typical inkblot leakage 30 s after fluorescein injection 
( a ) and 5 min later ( b ). No other leakages could be detected in this patient, but leakages in the periphery even of asymptomatic eyes are 
not uncommon. 
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depending on the nature of the protein in the subreti-
nal  fluid and the morphology of the altered RPE  [76, 
77] .
 A ‘smokestack leak’ is associated with pinpoint focal 
RPE leaks and present in only 7% of patients suffering 
from CSC. The majority (approx. 93%) has a more uni-
form dye spread also referred to as an ‘inkblot leak’. These 
pinpoint areas of hyperfluorescence tend to expand in the 
time course of the FA in a roundish fashion. The leakage 
points, regardless of their pattern, are usually distributed 
in a 1-mm-wide ring-shaped zone starting 0.5 mm from 
the center of the fovea. More than half of the leakages are 
found in the nasal quadrant, followed by the temporal 
quadrant, with approximately 35% of the leakages located 
there  [9, 16, 76] .
 Indocyanine Green Angiography 
 In CSC an inner choroidal staining can typically be ap-
preciated as a possible sign of fibrin. This staining appears 
in the midphase of the ICGA and fades in the late phase, 
which allows for differentiation from CNV  [32, 34] . ICGA 
is particularly helpful in chronic CSC patients as it is often 
very difficult to interpret areas of leakage on FA images, 
and sometimes even patients with no signs of fluorescein 
leakage show increased choroidal vascular hyperperme-
ability; however, ICGA usually does not contribute to 
treatment considerations, although some authors suggest 
the use of ICGA-guided photodynamic therapy (PDT) 
 [78–81] .
 Optical Coherence Tomography 
 Spectral-domain OCT (SD-OCT) is a helpful tool in ret-
inal diseases and also in CSC  [82] . As a noninvasive diag-
nostic device, it allows to capture fast and high-resolution 
sectional images of the retina. Several aspects of CSC have 
been investigated using OCT: it has been shown that the 
diameter of the choroidal vessels was significantly wider in 
affected eyes than in normal control eyes  [83] . Other groups 
showed differences in the architecture of the retinal area 
involved between acute and chronic CSC, implying that 
acute CSC patients have a significantly higher pure retinal 
layer volume but do not differ from chronic patients in 
terms of subretinal fluid  [84] . Furthermore, enhanced 
depth imaging, a new development of OCT, has provided a 
deeper insight into choroidal thickness. Several groups 
were able to prove that the choroid is thicker in patients suf-
fering from CSC in both the affected and the fellow eye 
compared with normal controls, strengthening the original 
idea of a hyperpermeable choroid  [85–88] . Other OCT 
findings include photoreceptor elongation as well as other 
defects in the inner segment/outer segment band which 
may correlate with visual acuity prognosis  [89–91]  (fig. 3–5).
ba c
d
 Fig. 3. Left eye of a 48-year-old male patient with a history of CSC showing typical features of CSC.  a Red-free 
photography.  b FA showing multiple inkblot leakages after 3 min.  c FAF with hyperautofluorescence as a pos-
sible sign of acute CSC.  d Corresponding SD-OCT with shallow PED and subretinal deposits, potentially a sign 
of fibrin. 
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 Fundus Autofluorescence Imaging 
 The RPE has been thoroughly evaluated in different 
diseases and its role in the pathology of CSC seems to be 
indisputable  [92–94] . This perception has been fortified 
by FAF findings. Due to the anatomic features of the RPE, 
detailed examination and imaging have been a challenge 
for many years. The introduction of FAF gave clinical 
ophthalmologists a sophisticated tool for evaluating RPE 
changes (fig. 6). Excitation of the RPE, and specifically of 
lipofuscin, with light of specific wavelengths provokes a 
characteristic fluorescence  [95–97] . Lipofuscin is a me-
tabolite that develops during the depletion of aged outer 
photoreceptors and accumulates in the RPE  [98] . Al-

















 Fig. 4. Right asymptomatic eye of the same 
48-year-old male patient as in figure 3.  a 
Red-free photography.  b FA image.  c FAF 
image.  d SD-OCT image. 
 Fig. 5.  a Multicolor image gained by simul-
taneous SD-OCT (Heidelberg Engineer-
ing, Heidelberg, Germany) image acquisi-
tion with 3 different color-selective laser 
sources. The value of this imaging tech-
nique for CSC has not been fully evaluated 
but may lie in the documentation of very 
early fundus alterations in CSC.  b ,  c Cor-
responding red-free photography ( b ) and 
SD-OCT image ( c ) of the same patient with 
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been supposed to have the strongest impact on retinal 
autofluorescence, newer studies could show that, particu-
larly in CSC, even precursors of lipofuscin that had not 
already accumulated in the RPE and were still beneath the 
neurosensory retina might contribute to the autofluores-
cence observed in CSC  [99] .
 Typical FAF patterns seen in acute CSC include in-
creased autofluorescence at the site of leakage, probably 
indicating an increased activity of the RPE as a response 
to augmented volumes of subretinal fluid  [100] . On the 
other hand, severe hypoautofluorescence – often associ-
ated with descending tracts that are surrounded by some-
what hyperautofluorescent borders as a sign of RPE dys-
function or atrophy – is appreciated particularly in chron-
ic cases  [99, 101] .
 Treatment 
 The course of the different pathogenic concepts of 
this disease is well reflected by the vast number of differ-
ent treatment options that have been evaluated and pro-
posed for CSC over time. These include observation and 
discontinuation of corticosteroids, laser approaches 
such as PDT, selective retinal therapy (SRT) and stan-
dard laser photocoagulation, intravitreal injections of 
anti-VEGF drugs and several systemic medications in-
cluding carbonic anhydrase inhibitors, β-blockers and 
particularly aldosterone antagonists. However, even to-
day, no therapy of CSC may be deemed to be the gold 
standard, although some therapies provide better evi-
dence for their efficiency than others; thus, of the large 
number of therapies suggested, only a few can be recom-
mended.
 As CSC is, in most cases, self-limiting with spontane-
ous resolution of the subretinal fluid, observation without 
additional treatment for the first 3 months is usually an 
appropriate first approach to handling this disease in pa-
tients without exogenous corticosteroid intake and no 
specific wish to accelerate the healing process. If possible, 
and after consulting the responsible physician, further 
management of risk factors includes discontinuation of 
steroids in patients taking these for other reasons, as well 
as reduction and avoidance of stress. In cases of chronic-
ity or recurrence, however, other treatment options 
should be considered.
 Photodynamic Therapy 
 Over the last couple of years, several groups have in-
vestigated a possible effect of PDT on CSC with benefi-
cial results in terms of visual acuity and morphologic 
reconstitution  [66, 80, 81, 102–105] . PDT is usually per-
formed by administering 6 mg/m 2 verteporfin (Visu-
dyne; Novartis Pharma) intravenously and subsequent 
activation of this dye by a laser light of 689 nm wave-
length at a (full) fluence of 50 J/cm 2 . The mechanism of 
action is postulated to include short-term choriocapil-
laris hypoperfusion and long-term choroidal vascular 
a b
 Fig. 6. Widefield FAF of the left ( a ) and right eye ( b ) of the same patient suffering from chronic CSC with typical tracks of pigment 
epithelial hypo- and hyperautofluorescence as a sign of long-lasting pigment epithelial lesions (hypoautofluorescence) mixed with acute 
pigment epithelial defects (hyperautofluorescence). 
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remodeling with subsequent reduction of vascular hy-
perpermeability and leakage  [65, 102] . Some side effects 
including RPE alterations, CNV and choroidal ischemia 
have been reported  [106] . In order to reduce these side 
effects, two modifications to conventional full-dose/flu-
ence PDT have been proposed: (1) half-dose PDT in 
which the amount of verteporfin is reduced to 3 mg/m 2 
with the same level of laser fluence (50 J/cm 2 ) or (2) half-
fluence PDT with the same concentration of verteporfin 
(6 mg/m 2 ) but with only 25 J/cm 2 of laser fluence. Both 
approaches yielded favorable results in terms of visual 
acuity recovery as well as subretinal fluid resolution in a 
large number of studies with fewer side effects com-
pared with conventional PDT  [65, 81] . In respect of mo-
dality, significantly more studies have been carried out 
to evaluate half-dose PDT and only a few to investigate 
half-fluence PDT. Half-dose PDT is concordantly re-
garded as being just as effective as full-dose PDT and is 
therefore recommended in cases of recurrent or chron-
ic CSC, particularly without severe PED  [107–109] . 
Some authors even recommend it in acute cases with 
symptoms lasting less than 3 months  [110] . Compared 
with laser photocoagulation, half-dose PDT may also fa-
cilitate an earlier resolution of macular detachment and 
the recovery of central retinal function  [111] . One group 
studied even lower doses of verteporfin but obtained in-
ferior results with one-third-dose PDT compared with 
half-dose PDT in terms of subretinal fluid resolution 
 [112] .
 Selective Retinal Therapy 
 In contrast to standard laser photocoagulation, SRT is 
supposed to apply laser spots only to the RPE without risk 
of scotoma by damaging the neurosensory retina  [113, 
114] . SRT is performed with a Q-switched, frequency-
doubled Nd:YLF laser beam with a wavelength of 527 nm 
 [115] . This selective treatment of the RPE is meant to trig-
ger the regeneration of the RPE and a long-term meta-
bolic increase at the chorioretinal junction  [116] . Three 
different studies and case series have been carried out to 
evaluate the effect of SRT in the setting of CSC  [115, 117, 
118] . However, all of them were conducted by the same 
group. A first case series in 2006, comprising 5 patients, 
showed promising preliminary results in terms of sub-
retinal fluid regression with coexistent PED without any 
cases of RPE rips  [115] . In the same year, another study 
with 27 patients could also show a very high subretinal 
fluid regression rate. It must be noted, though, that one 
third of these patients were treated in the first 3 months 
after the diagnosis of CSC. In general, these patients also 
showed final results superior to those of the other study 
participants, but a tendency toward spontaneous regres-
sion cannot be evaluated  [117] . In the third study, pub-
lished in 2011, Klatt et al.  [115] confirmed the previous 
results. Due to the low number of patients (n = 30) in-
cluded, however, a larger prospective clinical trial is war-
ranted to prove these findings. SRT is currently not com-
mercially available, nor do the results so far prove suffi-
cient effects in the treatment of CSC; therefore, SRT may 
be a promising treatment option in the future, but further 
studies are needed.
 Laser Photocoagulation 
 As in other retinal diseases such as clinically signifi-
cant macular edema in diabetic patients, laser spots are 
administered to focal leakages that have been identified 
by FA. The exact mechanism of laser photocoagulation 
is not known but may be based on sealing of leaking ves-
sels as well as activation of the pumping function of 
the RPE. Several studies have been carried out to evaluate 
the role of laser photocoagulation in CSC and good evi-
dence exists that photocoagulation leads to faster resolu-
tion of subretinal fluid  [68, 103, 119, 120] . However, sev-
eral studies showed that, in spite of faster subretinal fluid 
resolution, no significant impact on final visual acuity 
can be expected  [13, 119, 121] . Unlike SRT, standard 
photocoagulation has also been proposed for chronic 
cases of CSC and diffuse retinal pigment epitheliopathy 
but does not have any effect on bullous retinal detach-
ment, a rare form of CSC  [27, 122] . Laser photocoagula-
tion, however, needs thorough planning and careful ex-
ecution and no laser spots should be applied to very cen-
tral lesions; furthermore, long-term follow-up is 
necessary to detect cases of CNV, a rare but severe side 
effect.
 Although laser photocoagulation has proved its gen-
eral potency in CSC, possible side effects, particularly sco-
toma and the development of CNV, must be considered; 
therefore, laser photocoagulation should be mainly dis-
cussed for patients with long-standing CSC, possibly re-
fractory to other treatment approaches, or with a history 
of CSC in the fellow eye with an unfavorable visual acuity 
outcome.
 Carbonic Anhydrase Inhibitors 
 Prescription of oral acetazolamide is a widespread 
treatment option in CSC in spite of poor evidence in 
terms of outcome. Only one smaller case study and one 
prospective nonrandomized trial have been carried out to 
evaluate the influence of acetazolamide on the course of 
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CSC. While Gonzalez  [123] could show a reduction of 
metamorphopsia and at least stabilization of visual acuity 
in a few patients, Pikkel et al.  [124] could show that acet-
azolamide may shorten the subjective as well as objective 
time of clinical resolution but has no influence on final 
visual acuity prognosis or recurrence rates.
 Mineralocorticoid Receptor Antagonists 
 The exact mode of action of glucocorticoids in the 
pathogenesis of CSC is still not known, even though 
their prominent role is beyond controversy. It therefore 
seems obvious that one should search for treatment 
 options targeting this track. Glucocorticoids bind to 
their receptor but also to the mineralocorticoid receptor 
(MR) that belongs to the same family. MR are present 
in the kidney and the vasculature and were recently 
demonstrated to be expressed in different cell types of 
the neurosensory retina  [125] . Based on the observation 
of CSC aggravation by glucocorticoids and the known 
affinity of glucocorticoids for MR, Zhao et al.  [126] 
 hypothesized a potential inappropriate/excessive bind-
ing of glucocorticoids to MR and proved their assump-
tion in a rat model. Rat eyes received intravitreal injec-
tions of the glucocorticoid corticosterone. OCT before 
and after injection revealed significantly increased cho-
roidal thickening but no thickening of retinal vessels 
after 24 h, a finding similar to CSC. The effect of this 
glucocorticoid may have been triggered by glucocorti-
coid receptors or MR; therefore, other rats received in-
travitreal injections of aldosterone, which specifically 
binds to MR. In these rats, the same effects in terms of 
choroidal thickening were noticed and therefore an im-
portant role of MR deduced. Hence, treatment with an 
MR antagonist was proposed, and 2 patients with 
chronic nonresolved CSC were treated with oral eplere-
none for 5 weeks. A rapid resolution of the retinal de-
tachment and choroidal vasodilation as well as im-
provement in visual acuity was observed in these 2 pa-
tients, and consequently a larger study followed. This 
nonrandomized pilot study included 13 patients with 
chronic CSC (>3 months) treated with 25 mg/day of 
oral eplerenone for a week followed by 50 mg/day for 
1 month or 3 months; it was published in 2013 by Bous-
quet et al.  [127] . All patients showed a significant de-
crease in central macular thickness at 1 month and 
3 months under eplerenone treatment. Overall, not only 
a decrease in subretinal fluid but also an improvement 
in visual acuity was observed  [127] . Nevertheless, fur-
ther randomized trials are necessary to prove these con-
clusions.
 Conclusions 
 CSC is a clinical picture that ophthalmologists are fre-
quently confronted with. The therapeutic options are 
limited, although observation, reduction of stress and dis-
continuation of corticosteroids, where applicable, are of-
ten sufficient to overcome visual deterioration. Still, 40–
50% of patients suffer from recurrent forms of CSC, and 
as for chronic CSC patients, less favorable results in terms 
of visual acuity and morphologic reconstitution can be 
expected for these patients. In these cases, the only thera-
pies with good evidence for their efficiency are laser pho-
tocoagulation and PDT. Laser photocoagulation carries a 
risk of severe side effects including CNV and scotoma; 
PDT shows a lower risk of these but is associated with a 
high financial burden and therefore not available for ev-
ery patient.
 The first results of a study investigating MR antago-
nists are promising and agree with our own observations 
on CSC patients treated with spironolactone, another MR 
antagonist. MR antagonists such as eplerenone or spi-
ronolactone are relatively old drugs mainly used for car-
diovascular conditions such as hypertension. The most 
common side effect is increased urinary frequency; other 
side effects are rare but include dry skin, rashes and gyne-
comastia.
 Although further studies are needed to prove the value 
of MR antagonists in the treatment of CSC, from our per-
spective – against the background of the relatively small 
side effects of MR antagonists and very limited treatment 
options – it seems to be appropriate to recommend MR 
antagonists for patients suffering from CSC without signs 
of resolution within the first 8–12 weeks.
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